Zhaojun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhaojun Wang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Juan Chen
Ningxia Key Laboratory of Clinical and Pathogenic Microorganisms, Institute of Medical Science, General Hospital of Ningxia Medical University
4 shared publications - Jieda Cui
Guangzhou National Laboratory, Guangzhou International BioIsland, China
3 shared publications - Jing Xue
Institute of Human Stem Cell Research, General Hospital of Ningxia Medical University, Yinchuan, China
3 shared publications Furui Liu
The First School of Clinical Medicine, Ningxia Medical University, Yinchuan, China
2 shared publicationsHonglei Qi
The First School of Clinical Medicine, Ningxia Medical University, Yinchuan, China
2 shared publications- Hongyan Fu
Department of Key Laboratory of Ningxia Stem Cell and Regenerative Medicine, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, China
2 shared publications
Latest Publications
- Open Access
- 13 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (24) , e42931
Comparisons of mortality predictions of mROX, CURB-65, and APACHE II in patients with severe pneumonia: A retrospective cohort study
This study investigates the efficacy of the modified respiratory rate oxygenation (mROX) index, the CURB-65 score, their combination, and the Acute Physiology and Chronic Health Evaluation (APACHE) II score in predicting mortality among patients with severe pneumonia over various time frames. This retrospective cohort study analyzed data from patients admitted with severe pneumonia between January 2017 and December 2023. Patient demographics and 7-, 14-, and 28-day mortality outcomes were collected. The mROX, CURB-65, and APACHE II scores were computed upon hospital admission. The receiver operating characteristic (ROC) curve, time-dependent ROC curve, and survival curve analyses were conducted to assess the mortality predictive performance of mROX, CURB-65, and their combination, as well as APACHE II. The study included 140 patients, of whom 100 (71.4%) were male, with a median age of 65.0 years (interquartile range: 24.0). Within 28 days, 91 (65.0%) patients had succumbed. Compared to survivors, deceased patients exhibited higher CURB-65 scores and lower mROX indices. ROC analysis indicated that mROX outperformed CURB-65 and APACHE II in sensitivity, accuracy, and area under the curve (AUC) for predicting 28-day mortality. The combination of mROX and CURB-65 yielded the highest AUC (72.1%), suggesting enhanced mortality prediction accuracy. Time-dependent ROC and AUC analyses demonstrated the superior predictive capability of APACHE II within the initial 7 days post-admission, while mROX and CURB-65, alone or combined, were more effective for predictions beyond 14 days. Kaplan–Meier survival analysis indicated that higher mROX values and lower scores of CURB-65 and the combination of both were associated with reduced mortality risk, whereas APACHE II showed no significant difference in mortality risk. The mROX index, particularly when combined with CURB-65, improves mortality prediction accuracy in severe pneumonia patients beyond 14 days post-admission. The APACHE II score remains a valuable predictor within the first 7 days.
- 13 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (24) , e42931
Open AccessComparisons of mortality predictions of mROX, CURB-65, and APACHE II in patients with severe pneumonia: A retrospective cohort study
This study investigates the efficacy of the modified respiratory rate oxygenation (mROX) index, the CURB-65 score, their combination, and the Acute Physiology and Chronic Health Evaluation (APACHE) II score in predicting mortality among patients with severe pneumonia over various time frames. This retrospective cohort study analyzed data from patients admitted with severe pneumonia between January 2017 and December 2023. Patient demographics and 7-, 14-, and 28-day mortality outcomes were collected. The mROX, CURB-65, and APACHE II scores were computed upon hospital admission. The receiver operating characteristic (ROC) curve, time-dependent ROC curve, and survival curve analyses were conducted to assess the mortality predictive performance of mROX, CURB-65, and their combination, as well as APACHE II. The study included 140 patients, of whom 100 (71.4%) were male, with a median age of 65.0 years (interquartile range: 24.0). Within 28 days, 91 (65.0%) patients had succumbed. Compared to survivors, deceased patients exhibited higher CURB-65 scores and lower mROX indices. ROC analysis indicated that mROX outperformed CURB-65 and APACHE II in sensitivity, accuracy, and area under the curve (AUC) for predicting 28-day mortality. The combination of mROX and CURB-65 yielded the highest AUC (72.1%), suggesting enhanced mortality prediction accuracy. Time-dependent ROC and AUC analyses demonstrated the superior predictive capability of APACHE II within the initial 7 days post-admission, while mROX and CURB-65, alone or combined, were more effective for predictions beyond 14 days. Kaplan–Meier survival analysis indicated that higher mROX values and lower scores of CURB-65 and the combination of both were associated with reduced mortality risk, whereas APACHE II showed no significant difference in mortality risk. The mROX index, particularly when combined with CURB-65, improves mortality prediction accuracy in severe pneumonia patients beyond 14 days post-admission. The APACHE II score remains a valuable predictor within the first 7 days.
- Open Access
- 20 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1
Author Correction: Clinical characteristics and prognosis of patients treated as invasive pulmonary aspergillosis outside of severe immunosuppression
- 20 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1
Open AccessAuthor Correction: Clinical characteristics and prognosis of patients treated as invasive pulmonary aspergillosis outside of severe immunosuppression
- Open Access
- 27 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Clinical characteristics and prognosis of patients treated as invasive pulmonary aspergillosis outside of severe immunosuppression
This study aimed to identify clinical characteristics and develop a prognostic model for non-neutropenic patients with invasive pulmonary aspergillosis (IPA). A retrospective analysis of 151 IPA patients was conducted, with patients categorized into survival (n = 117) and death (n = 34) groups. Clinical data, including demographics, laboratory tests, and imaging, were collected. Multivariate Cox regression analysis identified glucocorticoid use (odds ratio [OR] = 30.223, 95% confidence interval [CI]: 2.676–341.306), intensive care unit admission (OR = 0.133, 95% CI: 0.023–0.758), and the arterial oxygen partial pressure/fractional inspired oxygen ratio (OR = 0.994, 95% CI: 0.990–0.999) as significant predictors of 28-day mortality. A prognostic model was developed based on these factors, showing high predictive accuracy (receiver operating characteristic curve area of 0.918). The model’s clinical applicability was validated through calibration curves, bootstrap internal validation, decision curve analysis, and clinical impact curves. Kaplan–Meier analysis further confirmed its utility, indicating a worse prognosis for high-risk patients within 50 days and the highest survival rate at 14 days. This novel model offers valuable insights for predicting survival in non-neutropenic IPA patients.
- 27 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessClinical characteristics and prognosis of patients treated as invasive pulmonary aspergillosis outside of severe immunosuppression
This study aimed to identify clinical characteristics and develop a prognostic model for non-neutropenic patients with invasive pulmonary aspergillosis (IPA). A retrospective analysis of 151 IPA patients was conducted, with patients categorized into survival (n = 117) and death (n = 34) groups. Clinical data, including demographics, laboratory tests, and imaging, were collected. Multivariate Cox regression analysis identified glucocorticoid use (odds ratio [OR] = 30.223, 95% confidence interval [CI]: 2.676–341.306), intensive care unit admission (OR = 0.133, 95% CI: 0.023–0.758), and the arterial oxygen partial pressure/fractional inspired oxygen ratio (OR = 0.994, 95% CI: 0.990–0.999) as significant predictors of 28-day mortality. A prognostic model was developed based on these factors, showing high predictive accuracy (receiver operating characteristic curve area of 0.918). The model’s clinical applicability was validated through calibration curves, bootstrap internal validation, decision curve analysis, and clinical impact curves. Kaplan–Meier analysis further confirmed its utility, indicating a worse prognosis for high-risk patients within 50 days and the highest survival rate at 14 days. This novel model offers valuable insights for predicting survival in non-neutropenic IPA patients.
- Open Access
- 27 March 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (7) , 1997-1998
Correction to: Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease
- 27 March 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (7) , 1997-1998
Open AccessCorrection to: Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease
- Open Access
- 17 March 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (7) , 1917-1929
Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease
Objective: Interstitial lung disease (ILD) is a common extramuscular manifestation of the anti-synthetase syndrome (ASS). Patients with ASS-ILD are at risk in developing a progressive fibrosing phenotype despite appropriate treatments. This study investigated the risk factors and the predictive value of multiple risk factors for progressive pulmonary fibrosis (PPF) in patients with ASS-ILD. Methods: Ninety patients with a diagnosis of ASS and evidence of ILD on high-resolution computed tomography (HRCT) were recruited. Among them, 72 participants completed follow-up for more than 12 months. These patients were further divided into a PPF-ASS group (n = 18) and a non-PPF-ASS group (n = 54). Logistic regression analysis was performed to investigate the risk factors for PPF. The predictive value of the combined risk factors for predicting PPF were analyzed by a ROC curve. Results: The PPF-ASS group had a higher rate of positive non-Jo-1 antibodies, a significantly higher neutrophil-to-lymphocyte ratio (NLR) and serum lactate dehydrogenase (LDH), and a significantly lower PaO2/FiO2 ratio and diffusing capacity for carbon monoxide (DLCO%pred) than the non-PPF-ASS group. In addition, elevated serum Krebs von den Lungen-6 (KL-6) level and reticular opacities were significantly more common, and corticosteroid monotherapy at onset was administered more frequently in the PPF-ASS group. The median duration of follow-up was 37.4 months, survival was poorer in the PPF-ASS group, and the overall survival was 88.9%. Multivariate regression analysis further revealed that positive non-Jo-1 antibodies, NLR, and KL-6 were independent risk factors for PPF. These combined indexes had good accuracy (area under the curve = 0.874) in predicting PPF in patients with ASS-ILD. Conclusion: Positive non-Jo-1 antibodies, NLR, and serum KL-6 are independent risk factors for PPF in patients with ASS-ILD. Monitoring these markers can potentially predict PPF in this group of patients. Key Points • Positive non-Jo-1 antibodies, NLR, and serum KL-6 are independent risk factors associated with PPF in patients with ASS-ILD. • Monitoring non-Jo-1 antibodies, NLR, and serum KL-6 can potentially predict PPF in patients with ASS-ILD.
- 17 March 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (7) , 1917-1929
Open AccessPrediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease
Objective: Interstitial lung disease (ILD) is a common extramuscular manifestation of the anti-synthetase syndrome (ASS). Patients with ASS-ILD are at risk in developing a progressive fibrosing phenotype despite appropriate treatments. This study investigated the risk factors and the predictive value of multiple risk factors for progressive pulmonary fibrosis (PPF) in patients with ASS-ILD. Methods: Ninety patients with a diagnosis of ASS and evidence of ILD on high-resolution computed tomography (HRCT) were recruited. Among them, 72 participants completed follow-up for more than 12 months. These patients were further divided into a PPF-ASS group (n = 18) and a non-PPF-ASS group (n = 54). Logistic regression analysis was performed to investigate the risk factors for PPF. The predictive value of the combined risk factors for predicting PPF were analyzed by a ROC curve. Results: The PPF-ASS group had a higher rate of positive non-Jo-1 antibodies, a significantly higher neutrophil-to-lymphocyte ratio (NLR) and serum lactate dehydrogenase (LDH), and a significantly lower PaO2/FiO2 ratio and diffusing capacity for carbon monoxide (DLCO%pred) than the non-PPF-ASS group. In addition, elevated serum Krebs von den Lungen-6 (KL-6) level and reticular opacities were significantly more common, and corticosteroid monotherapy at onset was administered more frequently in the PPF-ASS group. The median duration of follow-up was 37.4 months, survival was poorer in the PPF-ASS group, and the overall survival was 88.9%. Multivariate regression analysis further revealed that positive non-Jo-1 antibodies, NLR, and KL-6 were independent risk factors for PPF. These combined indexes had good accuracy (area under the curve = 0.874) in predicting PPF in patients with ASS-ILD. Conclusion: Positive non-Jo-1 antibodies, NLR, and serum KL-6 are independent risk factors for PPF in patients with ASS-ILD. Monitoring these markers can potentially predict PPF in this group of patients. Key Points • Positive non-Jo-1 antibodies, NLR, and serum KL-6 are independent risk factors associated with PPF in patients with ASS-ILD. • Monitoring non-Jo-1 antibodies, NLR, and serum KL-6 can potentially predict PPF in patients with ASS-ILD.
- 14 February 2022
- Published by SAGE Publications in Human Gene Therapy
- Vol. 33 (3-4) , 155-174
Adenoviral Transduction of Dickkopf-1 Alleviates Silica-Induced Silicosis Development in Lungs of Mice
Silicosis is an occupational disease caused by inhalation of silica dust, which is hallmarked by progressive pulmonary fibrosis associated with poor prognosis. Wnt/β-catenin signaling is implicated in the development of fibrosis and is a therapeutic target for fibrotic diseases. Previous clinical studies of patients with pneumoconiosis, including silicosis, revealed an increased concentration of circulating WNT3A and DKK1 proteins and inflammatory cells in bronchoalveolar lavage compared with healthy subjects. The present study evaluated the effects of adenovirus-mediated transduction of Dickkopf-1 ( Dkk1 ), a Wnt/β-catenin signaling inhibitor, on the development of pulmonary silicosis in mice. Consistent with previous human clinical studies, our experimental studies in mice demonstrated an aberrant Wnt/β-catenin signaling activity coinciding with increased Wnt3a and Dkk1 proteins and inflammation in lungs of silica-induced silicosis mice compared with controls. Intratracheal delivery of adenovirus expressing murine Dkk1 (AdDkk1) inhibited Wnt/β-catenin activity in mouse lungs. The adenovirus-mediated Dkk1 gene transduction demonstrated the potential to prevent silicosis development and ameliorate silica-induced lung fibrogenesis in mice, accompanied by the reduced expression of epithelia–-mesenchymal transition markers and deposition of extracellular matrix proteins compared with mice treated with “null” adenoviral vector. Mechanistically, AdDkk1 is able to attenuate the lung silicosis by inhibiting a silica-induced spike in TGF-β/Smad signaling. In addition, the forced expression of Dkk1 suppressed silica-induced epithelial cell proliferation in polarized human bronchial epithelial cells. This study provides insight into the underlying role of Wnt/β-catenin signaling in promoting the pathogenesis of silicosis and is proof-of-concept that targeting Wnt/β-catenin signaling by Dkk1 gene transduction may be an alternative approach in the prevention and treatment of silicosis lung disease.
- 14 February 2022
- Published by SAGE Publications in Human Gene Therapy
- Vol. 33 (3-4) , 155-174
Adenoviral Transduction of Dickkopf-1 Alleviates Silica-Induced Silicosis Development in Lungs of Mice
Silicosis is an occupational disease caused by inhalation of silica dust, which is hallmarked by progressive pulmonary fibrosis associated with poor prognosis. Wnt/β-catenin signaling is implicated in the development of fibrosis and is a therapeutic target for fibrotic diseases. Previous clinical studies of patients with pneumoconiosis, including silicosis, revealed an increased concentration of circulating WNT3A and DKK1 proteins and inflammatory cells in bronchoalveolar lavage compared with healthy subjects. The present study evaluated the effects of adenovirus-mediated transduction of Dickkopf-1 ( Dkk1 ), a Wnt/β-catenin signaling inhibitor, on the development of pulmonary silicosis in mice. Consistent with previous human clinical studies, our experimental studies in mice demonstrated an aberrant Wnt/β-catenin signaling activity coinciding with increased Wnt3a and Dkk1 proteins and inflammation in lungs of silica-induced silicosis mice compared with controls. Intratracheal delivery of adenovirus expressing murine Dkk1 (AdDkk1) inhibited Wnt/β-catenin activity in mouse lungs. The adenovirus-mediated Dkk1 gene transduction demonstrated the potential to prevent silicosis development and ameliorate silica-induced lung fibrogenesis in mice, accompanied by the reduced expression of epithelia–-mesenchymal transition markers and deposition of extracellular matrix proteins compared with mice treated with “null” adenoviral vector. Mechanistically, AdDkk1 is able to attenuate the lung silicosis by inhibiting a silica-induced spike in TGF-β/Smad signaling. In addition, the forced expression of Dkk1 suppressed silica-induced epithelial cell proliferation in polarized human bronchial epithelial cells. This study provides insight into the underlying role of Wnt/β-catenin signaling in promoting the pathogenesis of silicosis and is proof-of-concept that targeting Wnt/β-catenin signaling by Dkk1 gene transduction may be an alternative approach in the prevention and treatment of silicosis lung disease.
- Open Access
- 4 February 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (5) , e28807
Dedicator of cytokinesis 8 deficiency and hyperimmunoglobulin E syndrome
Rationale: Hyperimmunoglobulin E syndrome (HIES) is a rare and complex immunoregulatory multisystem disorder characterized by recurrent eczema, skin and sinopulmonary infections, elevated serum immunoglobulin E levels, and eosinophilia. Onset is most likely in childhood, although infrequent adult cases have been reported. Early diagnosis is important. The use of the National Institutes of Health scoring system and the HIES signal transducer and activation of transcription 3 score can standardize the diagnosis of HIES. Patient concerns: A 19-year-old woman presented with complaints of dry cough, pyrexia, dyspnea, and recurrent pneumonia. She had a history of milk allergy, recurrent eczema, suppurative otitis media, chalazia, and aphthous ulcers. Her parents had a consanguineous marriage. Diagnosis: HIES; severe pneumonia. Interventions: Voriconazole (200 mg iv 2 times/d) and flucytosine (1 g orally 4 times/d) for 3 weeks were administered, followed by oral administration of fluconazole for 3 weeks. Outcomes: The patient experienced near-complete remission of her respiratory symptoms. The patient was followed-up for one and a half years. During the follow-up, the patient presented again with cough and dyspnea and was again admitted to hospital. After being hospitalized for 3 weeks of antibiotic treatment, the patient experienced near-complete relief of her respiratory symptoms. Lessons: Regardless of patient age, it is important to consider the possibility of HIES when a patient has recurrent eczema, skin and sinopulmonary infections, elevated serum immunoglobulin E levels, and eosinophilia. Early diagnosis and intervention are essential to improve prognosis.
- 4 February 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (5) , e28807
Open AccessDedicator of cytokinesis 8 deficiency and hyperimmunoglobulin E syndrome
Rationale: Hyperimmunoglobulin E syndrome (HIES) is a rare and complex immunoregulatory multisystem disorder characterized by recurrent eczema, skin and sinopulmonary infections, elevated serum immunoglobulin E levels, and eosinophilia. Onset is most likely in childhood, although infrequent adult cases have been reported. Early diagnosis is important. The use of the National Institutes of Health scoring system and the HIES signal transducer and activation of transcription 3 score can standardize the diagnosis of HIES. Patient concerns: A 19-year-old woman presented with complaints of dry cough, pyrexia, dyspnea, and recurrent pneumonia. She had a history of milk allergy, recurrent eczema, suppurative otitis media, chalazia, and aphthous ulcers. Her parents had a consanguineous marriage. Diagnosis: HIES; severe pneumonia. Interventions: Voriconazole (200 mg iv 2 times/d) and flucytosine (1 g orally 4 times/d) for 3 weeks were administered, followed by oral administration of fluconazole for 3 weeks. Outcomes: The patient experienced near-complete remission of her respiratory symptoms. The patient was followed-up for one and a half years. During the follow-up, the patient presented again with cough and dyspnea and was again admitted to hospital. After being hospitalized for 3 weeks of antibiotic treatment, the patient experienced near-complete relief of her respiratory symptoms. Lessons: Regardless of patient age, it is important to consider the possibility of HIES when a patient has recurrent eczema, skin and sinopulmonary infections, elevated serum immunoglobulin E levels, and eosinophilia. Early diagnosis and intervention are essential to improve prognosis.